Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, \u3b22-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

Telomerase reverse transcriptase (TERT) promoter mutations were recently shown to drive telomerase activity in various cancer types, including medulloblastoma. However, the clinical and biological implications of TERT mutations in medulloblastoma have not been described. Hence, we sought to describe these mutations and their impact in a subgroup-specific manner. We analyzed the TERT promoter by direct sequencing and genotyping in 466 medulloblastomas. The mutational distributions were determined according to subgroup affiliation, demographics, and clinical, prognostic, and molecular features. Integrated genomics approaches were used to identify specific somatic copy number alterations in TERT promoter-mutated and wild-type tumors. Overall, TERT promoter mutations were identified in 21 % of medulloblastomas. Strikingly, the highest frequencies of TERT mutations were observed in SHH (83 %; 55/66) and WNT (31 %; 4/13) medulloblastomas derived from adult patients. Group 3 and Group 4 harbored this alteration in <5 % of cases and showed no association wit

Delta lake: high-performance ACID table storage over cloud object stores

Cloud object stores such as Amazon S3 are some of the largest and most cost-effective storage systems on the planet, making them an attractive target to store large data warehouses and data lakes. Unfortunately, their implementation as key-value stores makes it difficult to achieve ACID transactions and high performance: metadata operations such as listing objects are expensive, and consistency guarantees are limited. In this paper, we present Delta Lake, an open source ACID table storage layer over cloud object stores initially developed at Databricks. Delta Lake uses a transaction log that is compacted into Apache Parquet format to provide ACID properties, time travel, and significantly faster metadata operations for large tabular datasets (e.g., the ability to quickly search billions of table partitions for those relevant to a query). It also leverages this design to provide high-level features such as automatic data layout optimization, upserts, caching, and audit logs. Delta Lake tables can be accessed from Apache Spark, Hive, Presto, Redshift and other systems. Delta Lake is deployed at thousands of Databricks customers that process exabytes of data per day, with the largest instances managing exabyte-scale datasets and billions of objects